Tags

Type your tag names separated by a space and hit enter

Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
Clin Liver Dis 2016; 20(2):351-64CL

Abstract

Weight loss, regular exercise, and diet composition modification seem to improve biochemical and histologic abnormalities. Other therapies directed at insulin resistance, oxidative stress, cytoprotection, and fibrosis may also offer benefits. Insulin sensitizers and vitamin E seem to be the most promising; however, they cause side effects. A multifaceted approach of lifestyle modifications, weight loss, and pharmacotherapy can be used in combination, but no single treatment approach has proved universally applicable to the general population with nonalcoholic steatohepatitis (NASH). Continuous clinical and preclinical studies on existing and potential drugs are needed to improve treatment of nonalcoholic fatty liver disease/NASH.

Authors+Show Affiliations

Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Presbyterian, M2, C-Wing, 200 Lothrop Street, Pittsburgh, PA 15213, USA. Electronic address: ganesx@upmc.edu.Liver Transplantation, The Thomas Starzl Transplant Institute, UPMC Montefiore, Room N758.1, 3459 Fifth Avenue, Pittsburgh, PA 15213, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27063274

Citation

Ganesh, Swaytha, and Vinod K. Rustgi. "Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease." Clinics in Liver Disease, vol. 20, no. 2, 2016, pp. 351-64.
Ganesh S, Rustgi VK. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2016;20(2):351-64.
Ganesh, S., & Rustgi, V. K. (2016). Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease, 20(2), pp. 351-64. doi:10.1016/j.cld.2015.10.009.
Ganesh S, Rustgi VK. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2016;20(2):351-64. PubMed PMID: 27063274.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. AU - Ganesh,Swaytha, AU - Rustgi,Vinod K, Y1 - 2016/02/19/ PY - 2016/4/12/entrez PY - 2016/4/12/pubmed PY - 2017/1/17/medline KW - Antioxidants KW - Fatty acids KW - Insulin sensitizers KW - Lifestyle modification KW - NASH KW - Pharmacologic therapy KW - Weight loss SP - 351 EP - 64 JF - Clinics in liver disease JO - Clin Liver Dis VL - 20 IS - 2 N2 - Weight loss, regular exercise, and diet composition modification seem to improve biochemical and histologic abnormalities. Other therapies directed at insulin resistance, oxidative stress, cytoprotection, and fibrosis may also offer benefits. Insulin sensitizers and vitamin E seem to be the most promising; however, they cause side effects. A multifaceted approach of lifestyle modifications, weight loss, and pharmacotherapy can be used in combination, but no single treatment approach has proved universally applicable to the general population with nonalcoholic steatohepatitis (NASH). Continuous clinical and preclinical studies on existing and potential drugs are needed to improve treatment of nonalcoholic fatty liver disease/NASH. SN - 1557-8224 UR - https://www.unboundmedicine.com/medline/citation/27063274/Current_Pharmacologic_Therapy_for_Nonalcoholic_Fatty_Liver_Disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1089-3261(15)00106-3 DB - PRIME DP - Unbound Medicine ER -